Capricor Therapeutics
$5.92
24
+$0.02+0.34% Today
Statistics
Day High
-
Day Low
5.92
52W High
8.22
52W Low
3.3
Volume
17,838
Avg. Volume
134,040
Mkt Cap
152.6M
P/E Ratio
0
Dividend Yield
-
Dividend
-
Upcoming
Earnings
8NovExpected
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Next
-0.35
-0.32
-0.28
-0.25
Expected EPS
-0.32
Actual EPS
N/A
People Also Follow
This list is based on the watchlists of people on Stock Events who follow CAPR. It's not an investment recommendation.
Analyst Ratings
18$Average Price Target
The highest estimate is $18.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%
About
Health Technology
Biotechnology
Manufacturing
Pharmaceutical Preparation Manufacturing
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy (DMD), and other rare disorders. The company's development stage drug candidates for cardiosphere-derived cells include CAP-1002, a cardiac cell derived therapy, which is in phase II clinical trial for the treatment of patients with late-stage DMD; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of inflammatory conditions. The company was founded in 2005 and is headquartered in Beverly Hills, California.
Show more...
CEO
Linda Marban
Employees
26
Country
US
ISIN
US14070B3096
WKN
000A2PLU4